<DOC>
	<DOCNO>NCT01926509</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , PK MK-8892 participant pulmonary arterial hypertension . The primary hypothesis geometric mean MK-8892 area concentration time-curve Hour 0 24 hour ( AUC0-24hr ) participant PAH , equal great efficacious exposure humans 0.6 μM•hr .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Pharmacokinetics ( PK ) MK-8892 Participants With Pulmonary Arterial Hypertension ( PAH ) ( MK-8892-005 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>If female , pregnant breastfeeding . Females reproductive potential must agree agree use ( and/or partner use ) two ( 2 ) acceptable method birth control throughout study 2 week last dose study drug administer Body mass index ( BMI ) ≤34 kg/m^2 total body weight &gt; 40 kg ( &gt; 88 lb ) Has Group 1 pulmonary hypertension ( PAH ) define Dana Point 2008 Clinical Classification include : idiopathic PAH ( IPAH ) , Heritable PAH , Drug toxininduced PAH , PAH associate connective tissue disease congenital heart disease ( repaired simple cardiac defect least 1 year status post corrective surgery , residual intracardiac extracardiac shunt ) On stable regimen background therapy least 3 month prior start study drug Have history right heart catheterization within two year demonstrate pulmonary arterial hypertension Had pulmonary function test within one year start study medication demonstrate total lung capacity ( TLC ) &gt; 70 % predict , forced expiratory volume 1 second ( FEV1 ) &gt; 70 % predict Have hemoglobin &gt; 75 % low limit normal range Pulmonary hypertension subtypes include follow accord Dana Point 2008 Clinical Classification : human immunodeficiency virus ( HIV ) infection , portal hypertension , schistosomiasis , chronic hemolytic anemia , persistent pulmonary hypertension newborn ( PPHN ) , pulmonary hypertension due leave heart diseases systolic dysfunction , diastolic dysfunction valvular disease , pulmonary hypertension due lung disease and/or hypoxia ( e.g . chronic obstructive pulmonary disease , interstitial lung disease , pulmonary disease mixed restrictive obstructive pattern , sleepdisordered breathing , alveolar hypoventilation disorder , chronic exposure high altitude , developmental abnormality ) , chronic thromboembolic pulmonary hypertension ( CTEPH ) , hematologic disorder ( myeloproliferative disorder , splenectomy ) , systemic disorder ( sarcoidosis , pulmonary Langerhans cell histiocytosis , lymphangioleiomyomatosis , neurofibromatosis , vasculitis ) , metabolic disorder ( glycogen storage disease , Gaucher disease , thyroid disorder ) disorder ( tumoral obstruction , fibrosing mediastinitis , chronic renal failure dialysis ) Have secondary form pulmonary hypertension due pulmonary venoocclusive disease ( PVOD ) , pulmonary capillary hemangiomatosis ( PCH ) Resting systolic blood pressure &lt; 105 mmHg , rest heart rate ≥110/min Family history Long QT Syndrome Uncorrected hypokalemia hypomagnesemia Taking medication potent inhibitor inducer Cytochrome P450 3A4 ( CYP3A4 ) include limited cyclosporine , systemic itraconazole ketoconazole , glyburide , erythromycin , clarithromycin , telithromycin , nefazodone , protease inhibitor , carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , rifampicin , St John 's wort , diltiazem verapamil ) discontinue treatment &lt; 3 week prior start study . Concomitant medication , include anticoagulant , angiotensin convert enzyme ( ACE ) inhibitor , diuretic , bosentan , ambrisentan select calcium channel blocker ( e.g. , amlodipine ) may allow discretion investigator concurrence Sponsor . Unable refrain anticipates use organic nitrate ( e.g . nitroglycerin , isosorbide mononitrate , isosorbide dinitrate , pentaerythritol ) begin approximately 2 week start study throughout study Unable refrain anticipates use prostanoid therapy begin approximately 2 week start study throughout study Consume excessive amount alcohol , define great 3 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit [ 25 mL/1 ounce ] ) per day Major surgery donate blood within previous 8 week Participated another investigational study within 4 week History significant multiple and/or severe allergy Regular user illicit drug , history drug ( include alcohol ) abuse , within approximately 6 month Pregnant breastfeeding , expect conceive Interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>